Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN to Present at American Cough Conference
View:
Post by SkywalkerofLuke on Aug 22, 2022 4:01pm

AGN to Present at American Cough Conference

AGN.c ANGPF (a clinical stage Canadian pharmaceutical development company) is up 8.1% today. They announced earlier this month that they were invited to present the results from its Phase 2a Study of NP-120 for idiopathic pulmonary fibrosis and Chronic Cough, at the 9th American Cough Conference in June 2023.


Conference is the world's leading educational meeting for health care professionals involved in the research and management of patients with cough.


The most recent update from the Phase 2a Study showed Ifenprodil was much more effective at reducing cough in patients than initially reported. Good to see that AGN will be able to show these findings at such a big conference in the space.


https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/157/algernon-pharmaceuticals-invited-to-present-phase-2-ipf-and

Be the first to comment on this post
Algernon Pharmaceuticals Inc.